Study: NCT00249834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f
Description: GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotrophin (r-hCG)
Description: When at least 1 follicle greater than or equal to (\>=) 18 millimeter (mm) and 2 follicles \>=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.